Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXOB-001
- Development stage
- Phase 2
- Lead developer
- EXO Biologics
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratracheal
01
Overview
EXOB-001 is an investigational exosome-based therapy consisting of extracellular vesicles (EVs) derived from cultured human allogeneic umbilical cord mesenchymal stromal cells (hMSCs). It is being developed for the prevention of bronchopulmonary dysplasia (BPD) in preterm newborns. The drug is administered via intratracheal instillation, delivering EVs directly into the lungs. These vesicles are believed to reduce inflammation and promote tissue repair and regeneration by modulating immune responses, potentially preventing or reducing the severity of BPD. EXOB-001 has received Orphan Drug Designation from both the FDA and EMA for this indication and is currently undergoing Phase 1/2 clinical trials in extremely premature infants[1][2][3][4][5][8].
- Other names
- Allogeneic umbilical cord mesenchymal stromal cell-derived extracellular vesiclesMSC-derived exosomesUmbilical cord mesenchymal cells-derived extracellular vesicles
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))TGFB (GARP–latent transforming growth factor beta 1 complex)VEGFA (Vascular endothelial growth factor A)IL-6 (Interleukin 6)
Beyond the preview
Go deeper on EXOB-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXOB-001.